EQL Pharma AB
EQL | ST
Overview
Corporate Details
- ISIN(s):
- SE0005497732
- LEI:
- 549300Q8B2D2AE8GCW21
- Country:
- Sweden
- Address:
- Stortorget 1, 222 23 Lund
- Website:
- https://eqlpharma.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals, primarily in the Nordic region. The company conducts extensive development activities in collaboration with partners in Asia, Europe and India. Our strategy is to develop generic medicines in areas where the competition is limited, so-called niche generics. We do not focus on specific therapeutic areas, but rather on the opportunities we can identify in the Nordic market for prescription medicines sold in pharmacies or used in hospitals. Our entire business is based on us delivering the cheapest medicines to pharmacies and hospitals, in this way daily lowering the cost of high-quality drugs for patients and society.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-08 07:00 |
Earnings Release
|
Swedish | 1.2 MB | |
| 2025-08-08 07:00 |
Quarterly Report
|
English | 1.3 MB | |
| 2025-07-22 10:00 |
Pre-Annual General Meeting Information
Kallelse till årsstämma i EQL Pharma AB
|
Swedish | 281.5 KB | |
| 2025-07-22 10:00 |
Pre-Annual General Meeting Information
Notice of annual general meeting in EQL Pharma AB
|
English | 287.5 KB | |
| 2025-05-08 07:00 |
Earnings Release
|
Swedish | 1.3 MB | |
| 2025-05-08 07:00 |
Earnings Release
|
English | 1.3 MB | |
| 2025-03-07 08:30 |
Report Publication Announcement
New financial targets for the period 2024/25 – 2028/29
|
English | 351.6 KB | |
| 2025-03-07 08:30 |
Earnings Release
Nya finansiella mål för perioden 2024/25 - 2028/29
|
Swedish | 291.7 KB | |
| 2025-02-24 09:24 |
Board/Management Information
Valberedning inför årsstämman 2025
|
Swedish | 352.0 KB | |
| 2025-02-24 09:24 |
Post-Annual General Meeting Information
Nomination committee for the 2025 Annual General Meeting
|
English | 216.8 KB | |
| 2025-02-05 07:00 |
Annual Report
|
Swedish | 1.3 MB | |
| 2025-02-05 07:00 |
Interim Report
|
English | 1.3 MB | |
| 2025-01-31 12:35 |
Regulatory News Service
EQL Pharma AB slutför inkråmsförvärv av produktportfölj från Medilink A/S
|
Swedish | 319.0 KB | |
| 2025-01-31 12:35 |
M&A Activity
EQL Pharma AB completes the asset purchase of a product portfolio from Medilink…
|
English | 329.1 KB | |
| 2025-01-17 15:45 |
Capital/Financing Update
EQL Pharma AB successfully issues senior secured bonds
|
English | 323.8 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-17 | christer fåhraeus | Other | Sell | 100,000 | 8,620,000.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Heidelberg Pharma AG | Germany | HPHA | |
|
HELLENIC DYNAMICS PLC | United Kingdom | HELD | |
|
HIKMA Pharmaceuticals PLC | United Kingdom | HIK | |
|
HISAMITSU PHARMACEUTICAL CO.,INC. | Japan | 4530 | |
|
H. Lundbeck A | Denmark | HLUN | |
|
Hod-Assaf Industries Ltd. | Israel | HOD | |
|
HUDDLED GROUP PLC | United Kingdom | HUD | |
| Hutchmed (China) Limited | Hong Kong | N/A | ||
|
Iconovo AB | Sweden | ICO | |
|
iDNA Genomics Public Ltd | Cyprus | IDNA |